{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:10:11Z","timestamp":1752282611518},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T00:00:00Z","timestamp":1355270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1038\/leu.2012.364","type":"journal-article","created":{"date-parts":[[2012,12,12]],"date-time":"2012-12-12T07:40:25Z","timestamp":1355298025000},"page":"1567-1570","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells"],"prefix":"10.1038","volume":"27","author":[{"given":"M-C","family":"Wagner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Dziadosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J V","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D B","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,12]]},"reference":[{"key":"BFleu2012364_CR1","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2012364_CR2","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-05-0790","volume":"11","author":"JR Johnson","year":"2005","unstructured":"Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005; 11: 6414\u20136421.","journal-title":"Clin Cancer Res"},{"key":"BFleu2012364_CR3","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV . Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367\u20131373.","journal-title":"Clin Cancer Res"},{"key":"BFleu2012364_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542\u20132551.","journal-title":"N Engl J Med"},{"key":"BFleu2012364_CR5","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531\u20132541.","journal-title":"N Engl J Med"},{"key":"BFleu2012364_CR6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809\u2013819.","journal-title":"N Engl J Med"},{"key":"BFleu2012364_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/jnci\/91.2.163","volume":"91","author":"P le Coutre","year":"1999","unstructured":"le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R et al. In vivo eradication of human BCR\/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163\u2013168.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2012364_CR8","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008; 111: 4022\u20134028.","journal-title":"Blood"},{"key":"BFleu2012364_CR9","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007; 109: 3496\u20133499.","journal-title":"Blood"},{"key":"BFleu2012364_CR10","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","volume":"14","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485\u2013493.","journal-title":"Cancer Cell"},{"key":"BFleu2012364_CR11","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","volume":"114","author":"JL Snead","year":"2009","unstructured":"Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009; 114: 3459\u20133463.","journal-title":"Blood"},{"key":"BFleu2012364_CR12","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/leu.2009.45","volume":"23","author":"DK Hiwase","year":"2009","unstructured":"Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP . Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells. Leukemia 2009; 23: 1205\u20131206.","journal-title":"Leukemia"},{"key":"BFleu2012364_CR13","doi-asserted-by":"publisher","first-page":"e40853","DOI":"10.1371\/journal.pone.0040853","volume":"7","author":"DB Lipka","year":"2012","unstructured":"Lipka DB, Wagner M-C, Dziadosz M, Schn\u00f6der T, Heidel F, Schemionek M et al. Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells. PLoS One 2012; 7: e40853.","journal-title":"PLoS One"},{"key":"BFleu2012364_CR14","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","volume":"158","author":"C Heged\u0171s","year":"2009","unstructured":"Heged\u0171s C, \u00d6zvegy-Laczka C, Ap\u00e1ti \u00c1, Mag\u00f3csi M, N\u00e9met K, \u0150rfi L et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009; 158: 1153\u20131164.","journal-title":"Br J Pharmacol"},{"key":"BFleu2012364_CR15","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1124\/dmd.109.031302","volume":"38","author":"M Dohse","year":"2010","unstructured":"Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF et al. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Disposition 2010; 38: 1371\u20131380.","journal-title":"Drug Metab Disposition"},{"key":"BFleu2012364_CR16","doi-asserted-by":"crossref","unstructured":"Dziadosz M, Wagner M-C, Lipka DB, Fischer T, Bartels H . High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard. J Liq Chromatogr Relat Techno 2012.","DOI":"10.1080\/10826076.2011.636469"},{"key":"BFleu2012364_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu2012364_CR18","unstructured":"Manley PW, Cowan-Jacob S, Fendrich G, Liebetanz J, Mestan J, Martin N, Fabbro D . 100th Annual Meeting of the American Association for Cancer Research; 18\u201322 April, 2009; Abstract no. 3715."},{"key":"BFleu2012364_CR19","first-page":"1674","volume":"118","author":"PW Manley","year":"2011","unstructured":"Manley PW, Cowan-Jacob SW, Fendrich G, Jahnke W, Fabbro D . Nilotinib, in comparison to both dasatinib and imatinib, possesses a greatly prolonged residence time when bound to the BCR-ABL kinase SH1 domain. Blood (ASH Annu Meet Abstr) 2011; 118: 1674.","journal-title":"Blood (ASH Annu Meet Abstr)"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012364","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012364.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:22:20Z","timestamp":1648740140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,12]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["BFleu2012364"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.364","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,12]]},"assertion":[{"value":"12 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DBL received research funding from Novartis and honoraria from Novartis and BMS; FH and TF received honoraria from Novartis. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}